SLFN11 and neoplasm: Although temolozomide and talazoparib alone had marginal anti-tumor activity in NCI-H209 and NCI-H841 xenografts models, the combination induced marked synergy in NCI-H209 (high SLFN11) but not in NCI-H841 (low SLFN11) (Figure 5D).